Share, email, print, bookmark SOURCE reports.

[broadstreet zone=”52093″]

MARLBOROUGH – Urovant Sciences yesterday, June 18, announced it has entered into an exclusive 3-year distribution agreement with Sunovion Pharmaceuticals Inc. (Sunovion) for services to support the commercialization of vibegron, an investigational agent for the treatment of overactive bladder.

Both companies are subsidiaries of Sumitomo Dainippon Pharma Co., Ltd.

The co-promotion agreement will enable Urovant to leverage Sunovion’s commercial infrastructure to increase efficiency of the planned launch of vibegron.

[broadstreet zone=”53820″]

The agreement covers services such as account management, contract operations, third party logistics, and trade and retail distribution.

“Our affiliation with Sunovion through the Sumitomo Dainippon Pharma family of companies allows us to capitalize on the expertise and scale of Sunovion’s operational infrastructure,” said Kenton Stewart, SVP of Market Access of Urovant Sciences. “Through our combined efforts, we will accelerate preparations for our anticipated launch of vibegron in the U.S. market.”

“We are pleased to enter into this relationship with Urovant,” said Thomas Gibbs, SVP and Chief Commercial Officer of Sunovion. “This agreement will enable Urovant to access Sunovion’s well-established commercial capabilities as together we prepare for the launch of this important investigational medicine.”

[broadstreet zone=”59945″]

Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions.

Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s vision is to lead the way to a healthier world. The company’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything it does, Sunovion has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.

[broadstreet zone=”80100″]

Headquartered in Marlborough, Sunovion is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Europe Ltd., based in London, England, and Sunovion Pharmaceuticals Canada Inc., based in Mississauga, Ontario, are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc.


Above is a press release

By editor

Susan Petroni is the former editor for SOURCE. She is the founder of the former news site, which as of May 1, 2023, is now a self-publishing community bulletin board. The website no longer has a journalist but a webmaster.